Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: a post hoc analysis of RENAAL.

de Zeeuw D, Ramjit D, Zhang Z, Ribeiro AB, Kurokawa K, Lash JP, Chan J, Remuzzi G, Brenner BM, Shahinfar S.

Kidney Int. 2006 May;69(9):1675-82.

2.

Importance of baseline distribution of proteinuria in renal outcomes trials: lessons from the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study.

Zhang Z, Shahinfar S, Keane WF, Ramjit D, Dickson TZ, Gleim GW, Mogensen CE, de Zeeuw D, Brenner BM, Snapinn SM.

J Am Soc Nephrol. 2005 Jun;16(6):1775-80. Epub 2005 May 4.

3.

Pharmacokinetics, safety, and antihypertensive efficacy of losartan in combination with hydrochlorothiazide in hypertensive patients with renal impairment.

Dickson TZ, Zagrobelny J, Lin CC, Ritter MA, Snavely D, Ramjit D, Shahinfar S, Lo MW.

J Clin Pharmacol. 2003 Jun;43(6):591-603.

PMID:
12817522
4.

Losartan in patients with type 2 diabetes and proteinuria: observations from the RENAAL Study.

Shahinfar S, Dickson TZ, Ahmed T, Zhang Z, Ramjit D, Smith RD, Brenner BM; RENAAL Investigators.

Kidney Int Suppl. 2002 Dec;(82):S64-7.

5.

The losartan renal protection study--rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan).

Brenner BM, Cooper ME, de Zeeuw D, Grunfeld JP, Keane WF, Kurokawa K, McGill JB, Mitch WE, Parving HH, Remuzzi G, Ribeiro AB, Schluchter MD, Snavely D, Zhang Z, Simpson R, Ramjit D, Shahinfar S; RENAAL Study Investigators.

J Renin Angiotensin Aldosterone Syst. 2000 Dec;1(4):328-35.

PMID:
11967819
6.

Efficacy and tolerability of losartan in hypertensive patients with renal impairment. Collaborative Group.

Toto R, Shultz P, Raij L, Mitchell H, Shaw W, Ramjit D, Toh J, Shahinfar S.

Hypertension. 1998 Feb;31(2):684-91.

PMID:
9461241
7.

Nonpeptide glycoprotein IIb/IIIa inhibitors. 8. Antiplatelet activity and oral antithrombotic efficacy of L-734,217.

Cook JJ, Holahan MA, Lyle EA, Ramjit DR, Sitko GR, Stranieri MT, Stupienski RF 3rd, Wallace AA, Hand EL, Gehret JR, Kothstein T, Drag MD, McCormick GY, Perkins JJ, Ihle NC, Duggan ME, Hartman GD, Gould RJ, Lynch JJ Jr.

J Pharmacol Exp Ther. 1996 Jul;278(1):62-73.

PMID:
8764336
8.

Vampire bat salivary plasminogen activator evokes minimal bleeding relative to tissue-type plasminogen activator as assessed by a rabbit cuticle bleeding time model.

Mellott MJ, Ramjit DR, Stabilito II, Hare TR, Senderak ET, Lynch JJ Jr, Gardell SJ.

Thromb Haemost. 1995 Mar;73(3):478-83.

PMID:
7545321
9.

Nonpeptide glycoprotein IIb/IIIa inhibitors. 5. Antithrombotic effects of MK-0383.

Lynch JJ Jr, Cook JJ, Sitko GR, Holahan MA, Ramjit DR, Mellott MJ, Stranieri MT, Stabilito II, Zhang G, Lynch RJ, et al.

J Pharmacol Exp Ther. 1995 Jan;272(1):20-32.

PMID:
7815334
10.

Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis.

Ramjit DR, Lynch JJ Jr, Sitko GR, Mellott MJ, Holahan MA, Stabilito II, Stranieri MT, Zhang G, Lynch RJ, Manno PD, et al.

J Pharmacol Exp Ther. 1993 Sep;266(3):1501-11.

PMID:
8371153
12.

Effective thrombolysis without marked plasminemia after bolus intravenous administration of vampire bat salivary plasminogen activator in rabbits.

Gardell SJ, Ramjit DR, Stabilito II, Fujita T, Lynch JJ, Cuca GC, Jain D, Wang SP, Tung JS, Mark GE, et al.

Circulation. 1991 Jul;84(1):244-53.

PMID:
1905593
13.
14.

Supplemental Content

Loading ...
Support Center